This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Jan 2012

Baxter to Launch Second Phase III Trial on Alzheimer’s Drug

The trial will assess the safety and effectiveness of the drug as a potential treatment for the signs and symptoms of the neurological condition.

Baxter International will start a second Phase III clinical trial on its Gammagard liquid intravenous drug for the treatment of mild to moderate Alzheimer's disease.

 

The trial will involve 400 patients and will assess the safety and effectiveness of the drug as a potential treatment for the signs and symptoms of the neurological condition.

 

Ludwig Hantson, president of Baxter's bioscience business said,"If successful, Baxter's Phase III trials will support a regulatory filing for use of immunoglobulin therapy in the treatment of Alzheimer's disease."

 

Professor Hartmut Ehrlich, vice president of global research at Baxter's bioscience busin

Related News